中国肺癌杂志Issue(6)：365-368,4.DOI:10.3779/j.issn.1009-3419.2015.06.06
贝伐珠单抗联合培美曲塞加卡铂新辅助化疗方案对IIIa期肺腺癌手术安全性的影响
Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with IIIa Lung Adenocarcinoma
张松亮 1徐鹏飞 1袁成 1区伟1
作者信息
- 1. 510060广州，中山大学肿瘤防治中心，华南肿瘤国家重点实验室
- 折叠
摘要
Abstract
Background and objective Bevacizumab has showed its effcacy in advanced non-squamous lung can-cer. hTe aim of this study is to assess the safety of bevacizumab plus pemetrexed and carboplatin neoadjuvant chemotherapy in patients with lung adenocarcinoma.Methods25 patients with IIIa lung adenocarcinoma undergoing lobectemy or pneu-monectomy with mediastinal lymphadenectomy atfer induction bevacizumab (Bev) plus pemetrexed/carboplatin (PC) were selected. Toxicity of chemotherapy and postoperative complications were analyzed.Results Grade 3 or 4 neoadjuvant-related adverse events included fatigue (3 patients), neutropenia (3 patients), hypertension (1 patient). hTe adverse events thought to be related to bevacizumab included epistaxis in 2 patients (grade 1: 1; grade 2: 1) and hypertension in 3 patients (grade 1: 2; grade 3: 1). Postoperative complications included pneumonia in 2 patients, bronchial stump insuffciency in 1 case, atelectasis in 2 cases, and arrhythmia in 1 case. Hemorrhage events, thromboembolic events and wound-healing problems were not ob-served in the perioperative period.Conclusion hTe treatment modality of neoadjuvant Bev-PC appears to be safe and tolerant in patients with stage IIIa lung adenocarcinoma.关键词
肺肿瘤/贝伐珠单抗/新辅助化疗/安全性Key words
Lung neoplasms/Bevacizumab/Neoadjuvant chemotherapy/Safety引用本文复制引用
张松亮,徐鹏飞,袁成,区伟..贝伐珠单抗联合培美曲塞加卡铂新辅助化疗方案对IIIa期肺腺癌手术安全性的影响[J].中国肺癌杂志,2015,(6):365-368,4.
